Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

This trial is testing a new treatment sequence for men with high-risk locally advanced prostate cancer: hormone therapy and radiation to the prostate first, followed by surgical removal of the prostate (radical prostatectomy). Most patients receive hormone therapy or radiation OR surgery, not both in combination, so this study looks at whether the combined approach improves outcomes. **You may be eligible if...** - You are between 20 and 75 years old - You have biopsy-confirmed prostate cancer classified as high-risk (stage T3a or higher on MRI, Gleason score 8 or higher, or PSA of 20 ng/mL or higher) - You are willing and able to undergo a prostatectomy after hormone and radiation therapy - Your performance status is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have a rare form of prostate cancer (small cell, ductal, or neuroendocrine) - You have already received hormone therapy, radiation, or chemotherapy - Your cancer has spread to other parts of the body (metastatic) - You have had another cancer in the past 5 years - You have had recent serious heart events (heart attack, stroke, severe angina) in the past 6 months - You have uncontrolled HIV, active hepatitis, or a history of seizures Talk to your doctor to see if this trial is right for you.